Skip to main content
Emcure Pharmaceuticals Limited logo

Emcure Pharmaceuticals Limited — Investor Relations & Filings

Ticker · EMCURE ISIN · INE168P01015 LEI · 335800WYB6OIBY9EOZ42 BSE.NS Manufacturing
Open in API
Filings indexed 201 across all filing types
Latest filing 2025-07-09 Regulatory Filings
Country IN India
Listing BSE.NS EMCURE

About Emcure Pharmaceuticals Limited

https://www.emcure.com

Emcure Pharmaceuticals Limited is a research-driven global pharmaceutical organization engaged in the development, manufacturing, and marketing of a broad range of differentiated pharmaceutical products. The company maintains a diverse portfolio across several key therapeutic areas, including gynaecology, cardiovascular, oncology, anti-infectives, and HIV/AIDS. With a strong emphasis on research and development, Emcure operates multiple state-of-the-art manufacturing facilities and R&D centers globally. Its business model focuses on complex generics and innovative formulations, serving healthcare needs in over 70 countries. The company is recognized for its vertically integrated operations and commitment to high-quality standards, catering to both regulated and emerging markets worldwide.

Recent filings

Filing Released Lang Actions
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a confirmation letter under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, regarding securities dematerialisation for the quarter ended June 30, 2025. It is addressed to stock exchanges and signed by the company secretary and the registrar and share transfer agent. The content is a regulatory compliance confirmation rather than a financial report or announcement of financial results. The document length is short (3182 characters) and it does not contain financial statements or detailed financial data. It is primarily a regulatory filing confirming compliance with SEBI regulations.
2025-07-09 English
Acquisition
Capital/Financing Update Classification · 95% confidence The document is a formal disclosure made by Emcure Pharmaceuticals Limited to the National Stock Exchange of India and BSE Limited. It pertains to the incorporation of a wholly-owned subsidiary named Emcure Wellness Private Limited. The document references compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which governs disclosures related to corporate actions such as incorporation of subsidiaries. The content includes details about the subsidiary, such as share capital, nature of business, and ownership, but does not contain financial statements or performance data. It is an announcement of a corporate action (incorporation of a subsidiary) rather than a financial report or management discussion. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including incorporation of subsidiaries.
2025-07-04 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges notifying the closure of the trading window for insiders due to upcoming unaudited quarterly financial results. It references the Securities and Exchange Board of India regulations on insider trading and states the trading window will be closed from July 1, 2025, until 48 hours after the announcement of the unaudited financial results for the quarter ending June 30, 2025. There is no actual financial data or results presented in the document, nor is there a detailed report or analysis. The document is an announcement related to trading restrictions ahead of a financial report, not the report itself. The document length is short (1982 characters), and it serves as a regulatory notification. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance and regulatory announcements that do not contain substantive financial data or detailed reports.
2025-06-25 English
Updates
Regulatory Filings Classification · 95% confidence The document is an official communication addressed to stock exchanges (NSE and BSE) regarding a re-classification request under Regulation 31A of the SEBI Listing Regulations. It lists members of the Promoter and Promoter Group seeking re-classification to the Public category. The content is regulatory in nature, related to shareholding classification changes, but it is not a report, financial statement, or announcement of voting results. It is a formal regulatory filing informing the exchanges of a compliance-related matter. The document length is short (3234 characters), and it is not announcing a report publication but providing regulatory information. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2025-06-25 English
Action(s) initiated or orders passed
Regulatory Filings Classification · 95% confidence The document is a formal disclosure submitted to stock exchanges under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. It details a regulatory order received from the Regional Director, Ministry of Corporate Affairs, regarding compounding of an alleged violation of the Companies Act related to director retirement by rotation. The document is a notification of a regulatory order and does not contain financial statements, management discussion, or detailed report content. It is a regulatory announcement about a legal/regulatory matter affecting the company. The document length is 3835 characters, which is relatively short and consistent with a regulatory filing or announcement. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit into other specific categories like Legal Proceedings Report (LTR) because it is more of a compliance disclosure rather than a lawsuit or legal proceeding update.
2025-06-25 English
Updates
Capital/Financing Update Classification · 90% confidence The document is a formal disclosure addressed to the National Stock Exchange of India and BSE Limited, referencing SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. It provides Key Performance Indicators (KPIs) for the financial year ended March 31, 2025, with comparative data for the previous two years. The KPIs include financial metrics such as EBITDA, PAT, and RoCE, which are key financial performance indicators but do not constitute a full financial report like an Annual Report or Interim Report. The document is signed by the Company Secretary and Compliance Officer and includes certification by a Chartered Accountant firm. The content is focused on performance metrics disclosure under capital market regulations, which aligns with a Capital/Financing Update (CAP) rather than a full financial report or earnings release. The document length is just over 5,000 characters, containing substantive financial data but not a comprehensive financial statement or management discussion. Therefore, the best fit is Capital/Financing Update (CAP).
2025-06-21 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.